Litcius/Paper detail

Antibody response to the Janssen/Johnson Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases

Teresa Po‐Yu Chiang, Caoilfhionn M Connolly, Jake A. Ruddy, Brian J. Boyarsky, Jennifer L. Alejo, William A. Werbel, Allan B. Massie, Lisa Christopher‐Stine, Jacqueline Garonzik‐Wang, Dorry L. Segev, Julie J. Paik

2021Annals of the Rheumatic Diseases31 citationsDOIOpen Access PDF

Topics & Concepts

PopulationMedicineQuarantineCoronavirus disease 2019 (COVID-19)Epidemic modelDemographyPandemicIncidence (geometry)TrajectoryProjection (relational algebra)StatisticsMathematicsAlgorithmEnvironmental healthInternal medicineGeometryInfectious disease (medical specialty)AstronomyDiseasePhysicsSociologyPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesvaccines and immunoinformatics approaches
Antibody response to the Janssen/Johnson Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases | Litcius